Inserm, CESP Centre for Research in Epidemiology and Population Health, U1018, Epidemiology of Diabetes, Obesity and Chronic Kidney Disease Over the Lifecourse and Determinants of Early Nutrition, Villejuif, France.
Diabetes Metab. 2012 Mar;38 Suppl 3:S29-35. doi: 10.1016/S1262-3636(12)71532-X.
To evaluate the current procedures in French general practice of intensifying hypoglycaemic treatment in orally treated type 2 diabetic patients, according to the French recommendations.
Type 2 diabetic patient characteristics, HbA(1c) values, hypoglycaemic treatment and physician characteristics were collected from the electronic records of a panel of French general practitioners. Factors associated with the time until intensification of treatment were studied with the Cox model.
Among 17 493 orally treated patients with at least two available HbA(1c) values, 3118 patients (18%) required treatment intensification; 65% were on monotherapy, 31% on bitherapy and 4% on tritherapy. These patients were followed for a maximum of 14 months or until treatment was intensified. Treatment was intensified after the second high HbA(1c) value for 1212 patients (39%); this was immediate for 13% of these patients, within 6 months for 39% and within one year for 59%. Treatment intensification was less likely the older the patient, and more likely the higher the first HbA(1c) value, up to an HbA(1c) threshold of 9%.
Therapeutic inertia in caring for type 2 diabetic patients in France is frequent, at least for patients treated in general practice. This inadequate glycaemic control would be expected to have significant patient and public health consequences, with higher rates of associated diabetic complications.
根据法国建议,评估法国普通实践中强化口服治疗 2 型糖尿病患者降糖治疗的现行方案。
从法国一组全科医生的电子病历中收集 2 型糖尿病患者特征、HbA1c 值、降糖治疗和医生特征。使用 Cox 模型研究与治疗强化时间相关的因素。
在至少有两个 HbA1c 值的 17493 名口服治疗患者中,有 3118 名(18%)需要强化治疗;65%接受单药治疗,31%接受二联治疗,4%接受三联治疗。这些患者的随访时间最长为 14 个月或直至治疗强化。对于 1212 名(39%)患者,在第二次 HbA1c 值升高后立即强化治疗;其中 13%的患者立即强化,39%的患者在 6 个月内强化,59%的患者在 1 年内强化。随着患者年龄的增加,治疗强化的可能性越小,而首次 HbA1c 值越高,治疗强化的可能性越大,直到 HbA1c 值达到 9%。
法国 2 型糖尿病患者治疗中存在治疗惰性,至少在普通实践中是这样。这种不充分的血糖控制预计会对患者和公众健康产生重大影响,导致相关糖尿病并发症的发生率更高。